Renaissance Technologies
BCYC

Renaissance Technologies’s Bicycle Therapeutics BCYC Stock Holding History

Renaissance Technologies’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.5M Buy
1,533,400
+554,100
+57% +$2.54M 0.01% 1302
2026
Q1 		$4.54M Buy
979,300
+412,700
+73% +$2.36M 0.01% 1432
2025
Q4 		$4.01M Buy
566,600
+47,900
+9% +$353K 0.01% 1435
2025
Q3 		$4.01M Buy
518,700
+200,300
+63% +$1.51M 0.01% 1627
2025
Q2 		$2.21M Buy
318,400
+16,900
+6% +$135K ﹤0.01% 2046
2025
Q1 		$2.56M Buy
301,500
+32,000
+12% +$377K ﹤0.01% 1846
2024
Q4 		$3.77M Sell
269,500
-3,100
-1% -$66.4K 0.01% 1626
2024
Q3 		$6.17M Sell
272,600
-54,200
-17% -$1.25M 0.01% 1312
2024
Q2 		$6.61M Buy
326,800
+161,100
+97% +$3.64M 0.01% 1137
2024
Q1 		$4.13M Buy
165,700
+60,200
+57% +$1.28M 0.01% 1536
2023
Q4 		$1.91M Buy
105,500
+23,500
+29% +$389K ﹤0.01% 1979
2023
Q3 		$1.65M Buy
82,000
+11,100
+16% +$254K ﹤0.01% 1976
2023
Q2 		$1.81M Buy
70,900
+9,000
+15% +$209K ﹤0.01% 2065
2023
Q1 		$1.32M Buy
+61,900
New +$1.55M ﹤0.01% 2288
2022
Q3 		– Sell
-153,200
Closed -$2.57M – 4025
2022
Q2 		$2.57M Buy
153,200
+88,801
+138% +$1.87M ﹤0.01% 2011
2022
Q1 		$2.83M Sell
64,399
-8,780
-12% -$410K ﹤0.01% 1967
2021
Q4 		$4.45M Buy
+73,179
New +$4.04M 0.01% 1609
2021
Q3 		– Sell
-14,600
Closed -$443K – 3473
2021
Q2 		$443K Sell
14,600
-12,200
-46% -$369K ﹤0.01% 3008
2021
Q1 		$801K Sell
26,800
-54,400
-67% -$1.4M ﹤0.01% 2707
2020
Q4 		$1.46M Buy
81,200
+21,700
+36% +$419K ﹤0.01% 2304
2020
Q3 		$1.13M Sell
59,500
-15,200
-20% -$269K ﹤0.01% 2450
2020
Q2 		$1.18M Buy
74,700
+55,900
+297% +$859K ﹤0.01% 2463
2020
Q1 		$257K Buy
+18,800
New +$240K ﹤0.01% 3027

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies's BCYC Position: Q2 2026 in Review

Renaissance Technologies increased its Bicycle Therapeutics (BCYC) stake by 57% in Q2 2026, buying an estimated $2.54M and bringing the position to 1,533,400 shares worth $6.5M. The position accounts for 0.01% of the portfolio, ranked #1302.

Renaissance Technologies first reported a position in BCYC in Q1 2020 and has held it in 23 quarters since. The position peaked at $6.61M in Q2 2024. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Renaissance Technologies held 1,533,400 shares of Bicycle Therapeutics worth $6.5M as of Q2 2026.
  • Renaissance Technologies bought 554,100 Bicycle Therapeutics shares in Q2 2026, an estimated $2.54M.
  • Bicycle Therapeutics made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1302 holding.
  • Renaissance Technologies first reported a position in Bicycle Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Renaissance Technologies's Bicycle Therapeutics position peaked at $6.61M in Q2 2024.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.